Chinese Pharmaceutical Outlook 2008-2023

This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains.

Over 220 pages full of analysis, graphs, tables and charts – available to you today.

If you are interested in pharmaceutical business in China, you cannot afford to be without this report by visiongain’s leading authority on developing pharmaceutical markets.

• The growth of pharmaceutical markets in the developing nations has the potential to offset the slowdown of sales growth in developed markets of North America, Europe and Japan.

• Visiongain predicts that China will exhibit very strong pharma sales growth from 2008-2023. Rapid economic growth and a vast, currently under-served population, will drive that expansion. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors.

Visiongain’s Chinese Pharmaceutical Outlook 2008-2023 examines the exciting Chinese pharmaceutical market and industrial sector critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, surveying of key opinion leaders, SWOT analyses and discussion of qualitative factors. Societal, political, economic and commercial issues are covered. The result is a comprehensive market-based report with detailed analysis and informed opinion. This original 220+ page study contains 57 tables and 47 figures. We invite you to examine the table of contents included here.

In particular, visiongain’s Chinese Pharmaceutical Outlook 2008-2023 concentrates on the following themes:

• A forecast of the global pharmaceutical market from 2007-2023, with key issues discussed

• Forecasts of sales revenues and growth rates for Chinese pharmaceutical sales from 2007-2023, including key market segments such as Rx, OTC, domestic and foreign sales – all with comprehensive discussion

• Forecasts of sales for leading therapeutic areas and pharma products

• Revenue forecasts for clinical outsourcing in China and relevant discussion

• Revenue forecasts for contract manufacturing in China and relevant discussion

• Drivers and opportunities in the Chinese pharmaceutical sector

• Restraints and threats in that market and industry

• Discussion of key domestic players and important therapeutic areas, including biotechnology, drug development and joint ventures

• Discussion of regulatory, societal and economic issues

Why you should buy this report:

• To receive a comprehensive analysis of the Chinese pharma market and industry from 2007-2023, with both quantitative and qualitative aspects covered

• To discover predicted revenues, sales growth rates and other key metrics for the Chinese pharma sector from 2006-2023

• To determine the forces that influence pharmaceutical sales and related developments in China:

• Competitive characteristics of the market and industry

• Regulatory, technological, societal and political issues

• Drivers and restraints

• Strengths, weaknesses, opportunities and threats

• Expert opinion from China, as obtained by visiongain

• To find out where the Chinese market is heading - both commercially and technologically - including regulatory issues

• To determine key activities of leading companies

• To receive a comprehensive discussion of healthcare provision in China, both public and private.

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for over 80% of revenues for prescription drugs worldwide. However, there is great concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are striving to raise their profiles in the developing markets of Asia, Latin America and Eastern/Central Europe. Principal amongst those developing markets is the emergent demographic and economic colossus of China.

Growth of the pharmaceutical markets in developing nations will clearly surpass that of the established markets throughout the foreseeable future. That situation will provide one of the greatest opportunities ever available to the international pharmaceutical industry. Those strongly growing national economies drive the reform and broadening of healthcare systems, with increasing sales in all healthcare sectors. Improvements in both the quality and reach of these healthcare provisions will drive the sales of branded and generic drugs in particular. This report will help you to understand those developments and opportunities.

Other benefits to you when you order this report:

- Full searchable report when you buy the company or corporate editions

- Copies can be easily printed for offline reading

- PRICING -

- Single use licence $2995.00

- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only USD $5,995.00. This is not suitable for library usage.

- Allow your whole company to have access to this information for only USD $9,995.00. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD $13,995.00

April 2008
Table of Contents

Price
Single Use Licence $2995.00
Department Licence 5 Users $5,995.00
Company-wide Intranet Licence $9,995.00
Company over 2500 employees $13,995.00